Carbocyclic Ring Bonded Directly To The Piperazine Ring Patents (Class 514/255.03)
-
Publication number: 20030166637Abstract: The present invention relates to substituted piperazine derivatives of general formula 1Type: ApplicationFiled: October 9, 2002Publication date: September 4, 2003Inventors: Thorsten Lehmann-Lintz, Armin Heckel, Leo Thomas, Michael Mark
-
Publication number: 20030166643Abstract: This invention provides estrogen receptor modulators of formula I, having the structure 1Type: ApplicationFiled: December 11, 2002Publication date: September 4, 2003Applicant: WyethInventors: Robert E. McDevitt, Folake O. Adebi, Heather A. Harris, James C. Keith, Leo M. Albert
-
Publication number: 20030162789Abstract: The present invention relates to 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them. More particularly, it relates to 4-hydroxycinnamamide derivatives showing superior antioxidant activity compared to the known antioxidant compounds, their pharmaceutically acceptable salt, and pharmaceutical compositions containing them. It can be usefully used in treating neurodegerative diseases such as aging, cancer, diabetes, ischemic stroke, Parkin's disease, dementia and Huntinton's disease.Type: ApplicationFiled: November 22, 2002Publication date: August 28, 2003Inventors: No-Sang Park, Young-Sik Jung, Churl-Min Seong, Hee-Jong Lim, Joong-Ho Yoon, Jae-Yang Kong, Woo-Kyu Park
-
Publication number: 20030158207Abstract: The present invention relates to a compound selected from those of formula (I): 1Type: ApplicationFiled: July 16, 2002Publication date: August 21, 2003Inventors: Serge Labidalle, Jean-Paul Tillement, Bernard Testa, Romeo Cecchelli, Alain Le Ridant, Catherine Harpey, Michael Spedding, Esther Schenker
-
Publication number: 20030158208Abstract: The present invention provides a method of treating or preventing a novelty-seeking disorder such as pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction, drug addiction, alcohol addiction and sex addiction. using a compound which is a dopamine D4 receptor ligand, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 10, 2003Publication date: August 21, 2003Applicant: Pfizer Inc.Inventors: Stevin H. Zorn, Mark A. Sanner, Antor F. Fliri, Patricia A. Seymour
-
Publication number: 20030153578Abstract: The invention provides compounds of Formula (I): 1Type: ApplicationFiled: November 27, 2002Publication date: August 14, 2003Inventors: Daisy Joe Du Bois, Beihan Wang
-
Publication number: 20030149015Abstract: Phenylamino benzoic acid, benzamides, and benzyl alcohol derivatives of the formula 1Type: ApplicationFiled: December 10, 2002Publication date: August 7, 2003Inventors: Stephen Douglas Barrett, Alexander James Bridges, Donna Reynolds Cody, Annette Marian Doherty, David Thomas Dudley, Alan Robert Saltiel, Mel Conrad Schroeder, Haile Tecle
-
Publication number: 20030144291Abstract: The present invention relates to new piperidyl- or piperazinyl-substituted indan derivatives having the formula I 1Type: ApplicationFiled: January 9, 2003Publication date: July 31, 2003Inventors: Stefan Berg, Lennart Florvall, Svante Ross, Seth-Olov Thorberg
-
Publication number: 20030139423Abstract: New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1), wherein X N, CH, or C, however X may only be C when the compound comprises a double bond at the dotted line; R1 is OSO2CF3, OSO2CH3, SOR3, SO2R3, COR3, NO2, or CONHR3 and when X is CH or C R1 may also be CF3, CN, F, Cl, Br, or I; R2 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, or —(CH2)—R4; R3 is a C1-C3 alkyl, CF3, or N(R2)2; R4 is a C3-C6 cycloalkyl, 2-tetrahydrofurane or 3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed.Type: ApplicationFiled: November 21, 2002Publication date: July 24, 2003Inventors: Clas Sonesson, Bengt Andersson, Ingela Marianne Svan, Anders Kristoffer Lilja, Liselott Lilja Ronnqvist, Jenny Maria Carlberg, Susanna Waters, Nicholas Waters, Joakim Tedroff
-
Patent number: 6596706Abstract: The present invention relates to a compound represented by formula (1): wherein Q, which may have a substituent, represents an aryl group, a heterocyclic group, a diarylmethyl group, or an aralkyl group; R, which may have a substituent, represents a bicyclic nitrogen-containing heterocyclic group or a phenyl group; and Z represents a C1-C3 alkylene group, a C2-C4 alkenylene group, a C1-C3 alkylene group having one hydroxyl group, a carbonyl moiety, a C1-C2 alkylene group containing one carbonyl moiety at one end or an intermediate position of the carbon chain, or an oxalyl group; or salts thereof and a piperazine-cyclodextrin complex combined with a water-soluble cyclodextrin derivative. The complex exhibits enhanced water solubility, excellent stability, and low topical stimulation and is useful as a therapeutic agent for circulatory diseases and diseases of the brain region.Type: GrantFiled: May 8, 2000Date of Patent: July 22, 2003Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Masahiko Kikuchi, Yukihiko Nagase, Kaneto Uekama
-
Publication number: 20030119851Abstract: Disclosed are compounds of the formula: 1Type: ApplicationFiled: June 28, 2002Publication date: June 26, 2003Applicant: Neurogen Corporation, A Corporation of the State of DelawareInventors: Andrew Thurkauf, Xi Chen
-
Patent number: 6579870Abstract: The present invention provides pharmaceutically active compounds useful for the treatment of diseases or disorders of the central nervous system.Type: GrantFiled: June 8, 2001Date of Patent: June 17, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Eric Jon Jacobsen, Stephen J. King
-
Publication number: 20030105095Abstract: The present invention relates to a novel 4′-methanesulfonyl-biphenyl derivative having a structure of formula 1 and its pharmaceutically acceptable salts as a highly selective cyclooxygenase-2 inhibitor.Type: ApplicationFiled: October 3, 2002Publication date: June 5, 2003Applicant: CHEIL JEDANG CorporationInventors: Il Hwan Cho, Jee Woong Lim, Ji Young Noh, Jong Hoon Kim, Sang Wook Park, Hyung Chul Ryu, Je Hak Kim, Hyung Ok Chun, So Young Wang, Eun Young Lee
-
Patent number: 6569861Abstract: Disclosed are compounds of the formula: and the pharmaceutically acceptable salts thereof wherein Q, X, Y, Z, and R1 R9, and R12-R19 are defined herein. These compounds are selective modulators of MCH 1 receptors that are, therefore, useful in the treatment of a variety of metabolic, feeding, and sexual disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also disclosed.Type: GrantFiled: July 6, 2001Date of Patent: May 27, 2003Assignee: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Andrew Thurkauf, Alan Hutchison
-
Publication number: 20030092708Abstract: The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I): 1Type: ApplicationFiled: May 22, 2002Publication date: May 15, 2003Applicant: Japan Tobacco, Inc., a Japan CorporationInventors: Hisashi Shinkai, Kimiya Maeda, Hiroshi Okamoto
-
Publication number: 20030087914Abstract: The present invention relates to a novel process for the preparation of a compound of formula I: 1Type: ApplicationFiled: August 29, 2002Publication date: May 8, 2003Applicant: Pfizer Inc.Inventors: Joseph P. Rainville, Terry G. Sinay, Stanley W. Walinsky
-
Patent number: 6555541Abstract: The invention provides substituted phenyl compounds of general formula wherein R1, T, U and Ar are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.Type: GrantFiled: July 10, 2000Date of Patent: April 29, 2003Assignee: Astrazeneca UK LimitedInventors: Mark Furber, Timothy J Luker, Michael P Mortimore, Philip Thorne, Premji Meghani
-
Publication number: 20030078273Abstract: The treatment of addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction, and nicotine addiction using a heterocyclic amine, a phenylazacycloalkane, a cabergoline, or an aromatic bicyclic amine active agent, or a pharmaceutically acceptable derivative or salt of any said active agent is described herein.Type: ApplicationFiled: November 15, 2002Publication date: April 24, 2003Inventors: Richard W. Anderson, Sylvia S. McBrinn, David W. Robertson, Robert C. Marshall
-
Patent number: 6552022Abstract: The invention relates to therapeutic benzamide compounds of formula (I) wherein A, X, Z, R1, Y, R2, R3, are as defined herein, and physiologically acceptable salts, solvates or derivatives thereof. The present invention also provides pharmaceutical compositions, processes for the preparation of compounds of formula (I) and their use in the treatment of conditions mediated by ApoB-100 regulation.Type: GrantFiled: May 15, 2001Date of Patent: April 22, 2003Assignee: SmithKline Beecham CorporationInventor: Alain Claude-Marie Daugan
-
Patent number: 6548498Abstract: The present invention relates to new piperidyl- or piperazinyl-substituted indan derivatives of the formula I as (R)-enantiomers, (S)-enantiomers, or racemates in the form of a free base or pharmaceutically acceptable salts or solvates thereof. The present invention further relates to a process for the preparation of the compounds, to pharmaceutical compositions containing the compounds and to methods of treatment of 5-hydroxytryptamine-mediated disorders comprising administering the compounds.Type: GrantFiled: October 21, 1998Date of Patent: April 15, 2003Assignee: AstraZeneca ABInventors: Stefan Berg, Lennart Florvall, Svante Ross, Seth-Olov Thorberg
-
Patent number: 6548504Abstract: The present invention therefore provides, in a first aspect, a compound of formula (I) or a salt thereof: in which the group D is selected from a group of formula (A), (B) or (C) below: in which P is a monocyclic, bicyclic or tricyclic alicyclic ring containing up to 20 carbon atoms in the ring(s); A is a single bond, a C1-6alkylene or a C2-6alkenylene group; R1 is halogen, C1-6alkyl optionally substituted by one or more fluorine atoms, C3-6cycloalkyl, C1-6alkoxy, OCF3, hydroxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, C1-6alkoxyC1-6alkoxy, C1-6alkanoyl, amino, alkylamino or dialkylamino, SR11 where R11 is hydrogen or C1-6alkyl or R1 is aryl, arylC1-6alkyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur; n is 0, 1, 2 or 3; and R2 is hydrogen, C1-6alkyl, aryl, arylC1-6alkyl or C3-6cycloalkyl; or in which Ra is an alkyl group containing 1 to 20 carbon atoms oType: GrantFiled: July 19, 2000Date of Patent: April 15, 2003Assignee: SmithKline Beecham p.l.c.Inventors: Steven Mark Bromidge, Stephen Frederick Moss
-
Publication number: 20030069254Abstract: This invention relates to compounds which have generally 5-HT6 receptor affinity and which are represented by Formula (I): 1Type: ApplicationFiled: August 9, 2002Publication date: April 10, 2003Inventors: Jacob Berger, Robin Douglas Clark, Shu-Hai Zhao
-
Patent number: 6544996Abstract: Disclosed are compounds of the formula: or pharmaceutically acceptable addition salts thereof wherein: R1, R2, R3 R4 and R5, R6, R7, and R8 represent organic and/or inorganic substituents as defined herein, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.Type: GrantFiled: August 29, 2001Date of Patent: April 8, 2003Assignee: Neurogen CorporationInventors: Xiaoyan Zhang, Jennifer Tran, He Zhao, Andrew Thurkauf
-
Publication number: 20030050308Abstract: A method for treating Attention Deficit/Hyperactivity Disorder (ADHD) in humans and the symptoms associated therewith, inattentiveness, and hyperactivity with impulsivity, using eltoprazine and related compounds is provided.Type: ApplicationFiled: July 19, 2002Publication date: March 13, 2003Inventors: Daniela Brunner, Daniel W. Goodman
-
Publication number: 20030045521Abstract: Sulfohydroxamic acid diarylamines and derivatives thereof; compositions made from them; and methods of using them.Type: ApplicationFiled: September 13, 2002Publication date: March 6, 2003Inventor: Haile Tecle
-
Patent number: 6525199Abstract: A compound having the formula (I) or its salt, hydrate, hydrate salt or solvate: wherein R1 to R4 independently represent H, halogen, OH, alkoxy, optionally substituted alkyl, aryl, or aralkyl group, R5 represents H, optionally substituted alkyl, aryl, or aralkyl group, E1 represents O, S, or —NR6, where R6 represents H, an optionally substituted alkyl, aryl, or aralkyl group, E2 represents O, S, or —NR7, where R7 represents H, an optionally substituted alkyl, aryl, or aralkyl group, A represents CH, C(OH), or N, X represents H, halogen, alkoxy, or an optionally substituted alkyl group, and Q represents an optionally substituted phenyl group, phenoxy, phenylmethyl, or cycloalkyloxy group, where when E1 represents O or S, E2 does not represent O or S, which has an action of suppressing the cytotoxic Ca2+ overload and lipid peroxidation and effective for pharmaceutical preparation for the alleviation and treatment of symptoms due to ischemic diseases, etc.Type: GrantFiled: April 9, 2002Date of Patent: February 25, 2003Assignee: Suntory LimitedInventors: Hirokazu Annoura, Kyoko Nakanishi, Shigeki Tamura
-
Patent number: 6518272Abstract: This invention relates to compounds which have activity as 5-HT1A agonists and antagonists which may be useful for the treatment of anxiety, depression, cognitive deficits, and prostate cancer, having the formula wherein: X is a moiety selected from the group of: n is selected from the integers 1 through 5; R1 is optionally substituted aryl or mono or bicyclic heteroaryl, with a proviso that heteroaryl is not thiadiazole; R2 is H or alkyl; R3 is H, COR5, COOR5, and CONR5R6; R4 is H, alkyl, alkenyl, alkynyl, aryl, mono or bicyclic heteroaryl, aralkyl, and mono or bicyclic heteroaralkyl, wherein the aryl or heteroaryl groups are optionally substituted; R5 and R6 are H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl, and noradamantyl or R5 and R6 taken together may form a 5-7 membered azacyclic ring, optionally containing an additional heteroatom selected from O, S, or NR4; when R5 or R6 are chosen from cycloalkyl or cycloalkenyl, the cyclic group may optionallyType: GrantFiled: March 27, 2002Date of Patent: February 11, 2003Assignee: WyethInventors: Wayne E. Childers, Michael G. Kelly, Yvette L. Palmer, Edward J. Podlesny
-
Publication number: 20030027831Abstract: A series of aryl piperazine compounds of the formula: 1Type: ApplicationFiled: December 18, 2001Publication date: February 6, 2003Inventor: Yao-Chang Xu
-
Patent number: 6514976Abstract: Described herein is a compound of the formula wherein Ar′ is a mono or bicyclic aromatic or heteroaromatic radical substituted with one to three substituents selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R1 is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio; R2 is phenyl, naphthyl or (C3-C12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R3 is selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; X is —(C═O)—; or a pharmaceutically acceptable salt racemate, optical isomer or solvatType: GrantFiled: April 30, 2002Date of Patent: February 4, 2003Assignee: Eli Lilly and CompanyInventors: Daniel Timothy Kohlman, Yao-Chang Xu
-
Publication number: 20030008879Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.Type: ApplicationFiled: April 30, 2002Publication date: January 9, 2003Inventors: Daniel Timothy Kohlman, Yao-Chang Xu
-
Publication number: 20030008882Abstract: The present invention relates to compounds and pharmaceutical compositions which are proteomimetic and to methods for inhibiting the interaction of an alpha-helical protein with another protein or binding site. Methods for treating diseases or conditions which are modulated through interactions between alpha helical proteins and their binding sites are other aspects of the invention.Type: ApplicationFiled: May 8, 2002Publication date: January 9, 2003Inventors: Andrew D. Hamilton, Justin Ernst, Brendan P. Orner
-
Publication number: 20030004169Abstract: New substituted 4-phenyl N-alkyl)-piperazine and 4-phenyl-N-alkyl)-piperidine compounds of Formula (1) wherein X is N, CH, or C, however X may only be C when the compound comprises a double bind at the dotted line; R1 is CF3, OSO2CF3, OSO2CH3, SOR7, SO2R7, COR7, CN, OR3, NO2, CONHR3, 3-thiophene, 2-thiophene, 3-furane, 2-furane, F, Cl, Br, or I; R2 is F, Cl, Br, I, CN, CF3, CH3, OCH3, OH, and NH2; R3 and R4 are independently H or a C1-C4 alkyl; R5 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, or —(CH2)—R6; R6 is a C3-C6 cycloalkyl, 2-tetrahydrofurane, or 3-tetrahydrofurane; R7 is a C1-C3 alkyl, CF3, or N(R4)2, and pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed.Type: ApplicationFiled: June 18, 2002Publication date: January 2, 2003Inventors: Clas Sonesson, Bengt Andersson, Susanna Waters, Nicholas Waters, Joakim Tedroff
-
Publication number: 20020193383Abstract: The present invention is directed to novel 1-(N-phenylaminoalkyl)piperazine derivatives substituted at the position 2 of the phenyl ring. Pharmaceutical compositions comprising the compounds of the invention also are contemplated. The compounds of the present invention also are contemplated for use in treating neuromuscular dysfunction of the lower urinary tract in a mammal.Type: ApplicationFiled: April 22, 2002Publication date: December 19, 2002Applicant: Recordati S.A., Chemical and Pharmaceutical ComoanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
-
Patent number: 6492368Abstract: Novel compounds of the formula I in which X, Y, R1, R2 and R3 are as defined in Patent Claim 1 are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic disorders.Type: GrantFiled: March 31, 2000Date of Patent: December 10, 2002Assignee: Merck Patent GmbHInventors: Dieter Dorsch, Hanns Wurziger, Guido Melzer, Horst Juraszyk, Sabine Bernotat-Danielowski
-
Patent number: 6492355Abstract: The invention provides compounds of general formula in which m, A, R1 and Ar have the meanings defined in the specification; a process for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.Type: GrantFiled: June 1, 2000Date of Patent: December 10, 2002Assignee: AstraZeneca ABInventors: Lilian Alcaraz, Mark Furber, Michael P. Mortimore
-
Publication number: 20020173511Abstract: A method of treating Mild Cognitive Impairment has been discovered. The treatment method comprises administering an effective amount of a serotonergic agent, including, but not limited to dexnorfenfluramine. The agent can be any serotonergic agonist, partial agonist, serotonin reuptake inhibitor, or combinations of these agents. The treatment method also encompasses combinations of serotonergic agents and non-steroidal anti-inflammatory agents. The treatment method may also delay the onset of Mild Cognitive Impairment, dementia, or both.Type: ApplicationFiled: November 8, 2001Publication date: November 21, 2002Inventors: Richard J. Wurtman, Robert K. K. Lee
-
Publication number: 20020173505Abstract: A compound having agonist activity to the 5-HT4 receptor for use as a medicament and the use of said compound in the manufacture of a medicament for use in therapeutic or prophylactic treatment of disorders involving bronchocontraction of a human or animal body is described, as well as methods of treatment, wherein said compounds are administered. Further, a compound having antagonist activity to the 5-HT2a receptor for use as a medicament and the use of said compound in the manufacture of a medicament for use in therapeutic or prophylactic treatment or disorders involving bronchocontraction of a human or animal body is described, as well as methods of treatment, wherein said compounds are administered.Type: ApplicationFiled: October 29, 2001Publication date: November 21, 2002Inventor: Staffan Skogvall
-
Publication number: 20020169170Abstract: A method for potentiating the action of a serotonin reuptake inhibitor in increasing the availability of serotonin, norepinephrin and dopamine in the brain, comprising administering to a patient in need of such treatment a serotonin reuptake inhibitor in combination with an effective amount of a compound of the formula 1Type: ApplicationFiled: December 18, 2001Publication date: November 14, 2002Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O' Toole, Yao-Chang Xu, Tony Yantao Zhang
-
Publication number: 20020156075Abstract: This invention relates to compounds which have activity as 5-HT1A agonists and antagonists which may be useful for the treatment of anxiety, depression, cognitive deficits, and prostate cancer, having the formula 1Type: ApplicationFiled: March 27, 2002Publication date: October 24, 2002Applicant: Wyeth (formerly American Home Products Corporation)Inventors: Wayne E. Childers, Michael G. Kelly, Yvette L. Palmer, Edward J. Podlesny
-
Publication number: 20020156073Abstract: Provided, among other things, is a method of decreasing intraocular pressure or improving ocular accommodation in an animal, including a human, comprising administering an intraocular pressure decreasing or ocular accommodation improving amount of a compound of the formula I:Type: ApplicationFiled: December 31, 2001Publication date: October 24, 2002Inventors: Dilip Wagle, Martin Gall, Stanley C. Bell, Edmond J. LaVoie
-
Patent number: 6469011Abstract: Compound of formula (I): which is useful as a TXA2 and 5-HT2 receptor antagonist and pharmaceutical compositions containing the same.Type: GrantFiled: January 18, 2001Date of Patent: October 22, 2002Assignee: Les Laboratoires ServierInventors: Gilbert Lavielle, Bernard Cimetiere, Tony Verbeuren, Serge Simonet, Jean-Jacques Descombes
-
Publication number: 20020151539Abstract: The present invention relates to novel N-substituted azaheterocyclic compounds of the general formula 1Type: ApplicationFiled: March 14, 2002Publication date: October 17, 2002Inventors: Tine Krogh Jorgensen, Knud Erik Andersen, Rolf Hohlweg, Uffe Bang Olsen, Erik Fischer, Zdenek Polivka, Kaler Sindelar
-
Patent number: 6462033Abstract: This invention is directed toward a method of preparing a topical composition comprising ciprofloxacin and hydrocortisone. The method involves dispersing hydrocortisone with lecithin for greater than 45 minutes prior to combining hydrocortisone with the balance of the composition.Type: GrantFiled: July 16, 2001Date of Patent: October 8, 2002Assignee: Alcon Universal Ltd.Inventor: Onkar N. Singh
-
Publication number: 20020143011Abstract: Compounds of general formula (1) are described: 1Type: ApplicationFiled: March 14, 2001Publication date: October 3, 2002Applicant: Celltech Therapeutics, LimitedInventors: Graham John Warrellow, Ewan Campbell Boyd, Rikki Peter Alexander
-
Patent number: 6455528Abstract: The present invention relates to a piperazine compound of the formula wherein R1 and R2 are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4 and R5 are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6 and R7 are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R8 and R9 are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds.Type: GrantFiled: April 14, 2000Date of Patent: September 24, 2002Assignee: Mitsubishi Pharma CorporationInventors: Kunitomo Adachi, Yoshiyuki Aoki, Tokushi Hanano, Hiroshi Morimoto, Masao Hisadome
-
Patent number: 6451803Abstract: This invention relates to the use of a compound of the formula wherein m, R1, R2, R3, R4, R5 and X are as defined in the disclosure, for treating or preventing migraine, depression and other disorders for which a 5-HT1 agonist or antagonist is indicated.Type: GrantFiled: May 31, 2000Date of Patent: September 17, 2002Assignee: Pfizer INCInventor: Harry R. Howard
-
Patent number: 6451800Abstract: An objective of the present invention is to provide compounds having integrin &agr;v&bgr;3 antagonistic activity, GP IIb/IIIa antagonistic activity, and/or human platelet aggregation inhibitory activity, and therapeutic agents for treating integrin &agr;v&bgr;3-mediated diseases and for inhibiting platelet aggregation. The derivatives according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein A represents a five- to seven-membered heterocyclic ring containing two nitrogen atoms or the like; X and Z represent CH or a nitrogen atom; R4 and R5 represent alkyl, halogen or the like; Q represents >C=O, >CH2 or the like; R6 represents H, alkyl, aralkyl or the like; R7 represents H, alkynyl or the like; R8 represents H, substituted amino or the like; R9 represents H or alkyl; m is 0 to 5; n is 0 to 4; p is 2 or 3; and q is 0 or 1.Type: GrantFiled: July 28, 2000Date of Patent: September 17, 2002Assignee: Meiji Seika Kaisha, Ltd.Inventors: Keiichi Ajito, Shoichi Murakami, Minoru Ishikawa, Mikio Yamamoto, Dai Kubota, Shuichi Gomi, Mitsugu Hachisu, Kiyoaki Katano
-
Patent number: 6436925Abstract: Benzamides of the formula I and its tautomeric forms, possible enantiomeric and diastereomeric forms, E and Z forms, and possible physiologically tolerated salts, in which the variables have the following meanings: R1—C1-C6-alkyl, branched or unbranched, where one of the C atoms in this chain may be substituted by a phenyl ring, cyclohexyl ring, indolyl ring and an SCH3 group, and the phenyl ring in turn is substituted by by [sic] a maximum of two R4 radicals, where R4 [lacuna] hydrogen, C1-C4-alkyl, branched or unbranched, —O—C1-C4-alkyl, OH, Cl, F, Br, I, CF3, NO2, NH2, CN, COOH, COO—C1-C4-alkyl, NHCO—C1-C4-alkyl, and R2 can be NR5CO—R6 and NHR5SO2—R6, and R3 is chlorine, bromine, fluorine, C1-C6-alkyl, NHCO—C1-C4-alkyl, NHSO2—C1-C4-alkyl, NO2, —O—C1-C4-alkyl, CN, COOH, CONH2, COO—C1-C4-alkyl, SO2—C1-C4-alkyl, —SO2Ph, SO2NH—C1-C4-alkyl, iodine, SO2NH2 and NH2, and A can be aromType: GrantFiled: October 3, 2000Date of Patent: August 20, 2002Assignee: Abbott LaboratoriesInventors: Wilfried Lubisch, Achim Möller, Hans-Jörg Treiber, Monika Knopp
-
Publication number: 20020111359Abstract: A method of reducing, treating or preventing drug-mediated respiratory depression, muscle rigidity, or nausea/vomiting in an animal, incident to the administration to said animal of a mixed delta/mu opioid agonist or a respiratory depression-mediating drug, comprising administering to the animal receiving said drug an effective amount of a delta receptor agonist compound. Preferred examples of such delta receptor agonist compound include diarylmethyl piperazine compounds and diarylmethyl piperidine compounds, and pharmaceutical compositions thereof, having utility in medical therapy for reducing respiratory depression associated with certain analgesics, such as mu opiates.Type: ApplicationFiled: October 9, 2001Publication date: August 15, 2002Applicant: Ardent Pharmaceuticals, Inc.Inventors: Kwen-Jen Chang , Robert W. McNutt , Hugh O. Pettit , Michael J. Bishop
-
Publication number: 20020107245Abstract: Provided, among other things, is a method of treating, ameliorating or preventing certain fibrotic diseases or other indications in an animal, including a human, comprising administering an effective amount of a compound of the formula I:Type: ApplicationFiled: December 31, 2001Publication date: August 8, 2002Inventors: Dilip Wagle, Martin Gall, Stanley C. Bell, Edmond J. LaVoie